RMC-6236
RMC-6236 is a pharmaceutical drug with 7 clinical trials. Currently 7 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
6
Early Stage
0
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
7
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Clinical Trials (7)
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7